Google+ Facebook Twitter Twitter

Response to COVID-19 reduced in patients with blood cancers

Patients with blood cancers vary in their immune response to COVID-19 and can struggle to clear infection for many weeks, according to new research published in Cancer Cell.

By contrast, most patients with solid tumours, even those with advanced cancer, can mount an effective and lasting immune defence.

The team from King’s College London and the Francis Crick Institute analysed the blood of 76 cancer patients – 41 who had COVID-19 and 35 who had not been exposed to the virus. A total of 23 of the people with cancer had solid tumours, and 18 had blood cancers.

When they compared samples with the immune signatures from COVID-19 patients without cancer, they saw that patients with solid tumours had a similar immune response to those without cancer, regardless of cancer stage or if they were undergoing treatment. However, the immune response of patients with blood cancers varied considerably.

Image Credit | iStock

Related Articles

Focus on... autosomal dominant polycystic kidney disease

Kamila Orzechowska, a final-year student at Coventry University, looks at the role of epidermal growth factor receptors and microbial infections in autosomal dominant polycystic kidney disease.

From animals to humans...

Dawn Alderson gives a personal account of her career change in the middle of the pandemic.

Tech news: May

This month's top tech news stories

Medical imaging dimensionality mismatch

In medical imaging, 3D images are typically displayed on a 2D monitor.